Planta Med 2013; 79 - PK9
DOI: 10.1055/s-0033-1348633

Natural Product Inhibitors of the Arginine-Specific Protease Activity of MALT1

A Castro 1, EA Smith 1, LR Haugh Krumpe 1, 2, BR O'Keefe 1, LM Staudt 3, JB McMahon 1, KR Gustafson 1
  • 1Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Bldg 562, Rm 201, Frederick, MD 21702
  • 2SAIC-Frederick, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702
  • 3Metabolism Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892

MALT1 (mucosa-associated lymphoid tissue lymphoma translocation protein 1) is a multi-domain protein that plays a critical role in NF-κB activation. It has been implicated in lymphomas, multiple myeloma, and epithelial cancers, and it plays a key role in regulating the immune response to infection. MALT1 possesses a proteolytic paracaspase domain that cleaves arginine-containing substrates, and inhibition of this protease activity by RNAi has been shown to reduce survival of various lymphoma cell lines. Thus, molecularly-targeted strategies directed towards MALT1 protease activity have significant therapeutic potential. An enzymatic high-throughput assay that employed full-length human MALT1 and a fluorescently labeled peptide substrate (acetyl-Leu-Arg-Ser-Arg-4-methyl-coumaryl-7-amide) was developed and used to screen extracts from the NCI Natural Products Repository. A number of extracts were active in this screen and they were subjected to detailed chemical study. Bioassay-guided fraction of these extracts and the resulting MALT1 inhibitory natural products will be described.